Actus Oncology targeted radiopharmaceuticals thesis
Actus Oncology presents a high-upside biotech thesis leveraging its mini-protein platform to precisely deliver radioactive payloads with built-in competitive moats.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.